 PENNINGTON, N.J. and SAN DIEGO, April 15, 2021 PRNewswire -- OncoSec Medical Incorporated NASDAQ:ONCS the Company or OncoSec, a biotechnology company focused on cytokine-based intratumoral immunotherapies, today announced that it will be presenting encore interim data from its KEYNOTE-695 registration-enabled Phase 2b clinical trial evaluating TAVOTM tavokinogene telseplasmid, a DNA plasmid-based interleukin-12 IL-12, in combination with KEYTRUDA pembrolizumab in rigorously defined anti-PD1 checkpoint resistant metastatic melanoma patients at the 10th World Congress of Melanoma. 